Toby Kent
Toby Kent, head of medical affairs, oncology, AbbVie UK
HSJ PartnersCapacity-sparing innovations in blood cancer could unlock NHS potential
Toby Kent of AbbVie UK highlights how the forthcoming NHS 10-year plan is a crucial opportunity to set out a vision for medicines’ role as capacity-sparing innovations which could reduce pressures on infusion services in blood cancer and improve treatment choices for people affected by cancer.